



Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

## **COMPLETE IF KNOWN**

Application Number	10/696,178
Filing Date	10/29/2003
First Named Inventor	KATERINA LEFOTHERIS
Art Unit	1616
Examiner Name	PRYOR, ALTON NATHANIEL
Attorney Docket Number	QA0237 DIV 1

Sheet 1 of 1

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	1A	Davis, et al., "Substituted (Pyrroloamino)pyridines: Potential Agents for the Treatment of Alzheimer's Disease", J. Med. Chem., Vol. 39, pp. 582-587 (1996)	
	1B	Henry, et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs Future, Vol. 24, pp. 1345-1354 (1999)	
	1C	Jaffari et al., "Some Oxidation Reactions of Monochloramine", J. of Chem. Soc., pp. 823-826 (1971)	
	1D	Migliara, et al., "New synthesis of some 1,2,5-benzothiadiazepine 1,1-dioxide derivatives. I.", J. of Heterocyclic Chem., Vol. 16, pp. 833-834 (1979)	
	1E	Moreland, et al., "Etanercept Therapy in Rheumatoid Arthritis", American College of Physicians - Am. Soc. Of Internal Medicine, Vol. 130, pp. 478-486 (1999)	
	1F	Neunhoeffter, et al., "Cycloadditionen mit Methoxy-und Dialkylamino-1,2,4-Triazinen" Justus Liebigs Ann. Chem., Vol. 9, pp. 1413-1420 (1977); Chem Abstr., Vol. 88, 121113q, (1978)	
	1G	Patil, et al., "Synthesis of pyrrolo[2,1-f][1,2,4]triazine congeners of nucleic acid purines via the N-amination of 2-substituted pyrroles", J. Heterocyclic Chem., Vol. 31, pp. 781-807 (1994)	
	1H	Quintela, et al., "A ready one-pot preparation for pyrrolo[2,1-f]-[1,2,4]triazine and pyrazolo[5,1-c]pyrimido[4,5-e]-[1,2,4]triazine derivatives " Tetrahydron, Vol. 52, pp. 3037-3048 (1996)	
	1I	Rankin, et al., "The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis", British J. of Rheumatology, Vol. 34, pp. 334-342 (1995)	
	1J	Salituro, et al., "Inhibitors of p38 MAP Kinase: Therapeutic intervention in cytokine- mediated diseases", Current Medicinal Chem., Vol. 6, pp. 807-823 (1999)	
	1K	Svete, et al., "2-Benzoyl-2-ethoxycarbonylvinyl-1 and 2-Benzoylamino-2-methoxy-carbonylvinyl-1 as N-Protecting Groups in Peptide Sythesis. Their Application in the Synthesis of Dehydropeptide Derivatives Containing N-Terminal 3-Heteroaryl-amino-2,3-dehydroalanine", Heterocyclic Chem., Vol. 34, pp. 177-193 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant